Tirzepatide
Also known as: LY-3298176, LY3298176, Mounjaro, tirzepatide, twincretin, Zepbound
Source Tirzepatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Tirzepatide is a synthetic peptide that activates both the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors. It is administered as a once‑weekly subcutaneous injection and is approved for the treatment of type 2 diabetes and obesity. Clinical trials have shown substantial weight loss, improved glycaemic control, and potential benefits in heart failure with preserved ejection fraction and obstructive sleep apnea, positioning it as a versatile therapy for metabolic and cardiometabolic disorders.
Mechanism of Action
Tirzepatide binds to and activates GIP receptors and GLP‑1 receptors on pancreatic β‑cells, enhancing glucose‑dependent insulin secretion while suppressing glucagon release. Concurrently, GLP‑1 receptor activation slows gastric emptying and promotes satiety via hypothalamic pathways. The combined GIP/GLP‑1 signaling produces synergistic effects on appetite reduction, energy expenditure, and glucose homeostasis, leading to weight loss and improved glycaemic metrics.
What the Research Shows
In the SURMOUNT‑1 obesity trial (n=2,539), weekly tirzepatide (5‑15 mg) produced mean weight reductions of 15‑21% over 72 weeks versus 3% with placebo, with 50‑57% achieving ≥20% loss. The SURMOUNT‑5 head‑to‑head study (n=751) showed tirzepatide lowered weight by 20.2% compared with 13.7% for semaglutide and reduced waist circumference by 18.4 cm versus 13.0 cm. A network meta‑analysis of 76 trials identified tirzepatide as delivering the greatest HbA1c fall (≈‑2.1%) among GLP‑1RAs. In the SUMMIT heart‑failure trial (n=731), tirzepatide lowered the composite of cardiovascular death or worsening HF (HR 0.62) and improved quality‑of‑life scores. Two phase‑3 OSA trials (n≈1,200) demonstrated a ~20‑30 event per hour reduction in apnea‑hypopnea index versus placebo. Gastro‑intestinal events were the most common adverse effects across studies.
Reported Benefits
Tirzepatide consistently produces large, sustained weight loss (up to 20% of body weight) and significant reductions in waist circumference. It delivers the strongest glycaemic improvements among GLP‑1‑based therapies, lowering HbA1c by about 2 percentage points. Early cardiovascular data suggest a lower risk of death or worsening heart failure in patients with HFpEF, and sleep‑apnea studies show marked reductions in apnea severity. These benefits extend across patients with obesity, type 2 diabetes, and selected cardiometabolic conditions.
Limitations of the Evidence
Evidence is currently limited to clinical trial populations, often excluding patients with advanced kidney disease or severe comorbidities. Long‑term safety beyond the 2‑year trial periods is not fully established. Gastro‑intestinal side effects lead to discontinuation in up to 7% of participants at higher doses. Comparative data are primarily versus placebo or semaglutide; head‑to‑head trials are few. The cardiovascular and sleep‑apnea benefits derive from single trials, requiring replication before definitive conclusions.
Safety Considerations
The most frequent adverse events are nausea, vomiting, diarrhoea and constipation, usually mild‑to‑moderate and occurring during dose escalation. Discontinuation due to adverse events ranged from 4‑7% with tirzepatide versus 2‑3% with placebo. Caution is advised when combined with insulin or sulfonylureas due to hypoglycaemia risk, and clinicians should monitor for pancreatitis, gallbladder disease, and renal function. No specific contraindications were reported in the cited trials.
How It Is Administered
Tirzepatide is supplied as a sterile injectable solution for subcutaneous administration once weekly. Dosing begins at a low level and escalates over approximately 20 weeks to a target dose of 5, 10 or 15 mg, depending on tolerability and therapeutic goals. No oral formulation is currently available.
Routes of Administration
Goals & Uses
- Chronic Weight ManagementObesityHigh
- Cardiovascular risk reductionCardiovascularModerate
- Non-alcoholic fatty liver disease (MASH/NASH)Hepatic / MetabolicModerate
- Reduction of obstructive sleep apnea severityPulmonary / SleepModerate
- Appetite suppression and satietyNeurological / BehavioralHigh
- Weight loss / obesity managementMetabolicHigh
- Glycemic control in type 2 diabetesMetabolicHigh
- Type 2 diabetes mellitusMetabolicHigh
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)OncologicHigh
- Multiple endocrine neoplasia syndrome type 2 (MEN2)OncologicHigh
- Medullary thyroid carcinoma (MTC)OncologyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Type 1 diabetes mellitusEndocrineHigh
- Multiple endocrine neoplasia type 2 (MEN 2)OncologyHigh
- Hypersensitivity to tirzepatide or excipientsImmunologicalHigh
Adverse Effects
- PancreatitisGastrointestinalRareInflammation of the pancreas
- HypoglycemiaMetabolicUncommonAbnormally low blood glucose
- Injection site reactionsLocalCommon
- ConstipationGastrointestinalCommonReduced bowel frequency or difficulty passing stool
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- Insulin and insulin secretagogues (e.g., sulfonylureas)High
- Oral contraceptivesLowDelayed gastric emptying may affect absorption timing
- InsulinModerateMay increase risk of low blood sugar
- WarfarinModerate
- CyclosporineModerate
- SulfonylureasModerateMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patients (<18 years)AgeRelative
- Lactation / BreastfeedingReproductiveRelative
- Pediatric patientsAgeAbsolute
- Severe renal impairment / End-stage renal diseaseRenalRelative
- History of pancreatitisGastrointestinalRelative
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)RenalRelative
- Severe gastrointestinal diseaseGastrointestinalRelative
Regulatory Status
- European UnionApprovedApproved: type 2 diabetes mellitus, obesityEMA approval for diabetes (2022) and obesity (2023).
- United StatesApprovedApproved: type 2 diabetes mellitus, chronic weight managementFDA approved under brand Mounjaro.
- United KingdomApprovedApproved: type 2 diabetes mellitus, obesityMHRA approval aligned with EMA.
FDA approved (2022) for type 2 diabetes; FDA approved (2023) for chronic weight management under the brand Mounjaro. EMA approval for diabetes (2022) and obesity (2023).
Evidence & Sources
- Journal ArticleModerateJastreboff AM, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModeratePacker M, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateAronne LJ, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighYao H, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateMalhotra A, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateJastreboff AM, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
How does tirzepatide cause weight loss?
By activating both GIP and GLP‑1 receptors, tirzepatide reduces appetite and slows gastric emptying, while improving insulin sensitivity. These mechanisms together lead to decreased calorie intake and increased satiety, resulting in substantial weight loss over months.
Is tirzepatide approved for heart failure or sleep apnea?
Regulatory approval currently covers type 2 diabetes and obesity. The heart‑failure with preserved ejection fraction and obstructive sleep‑apnea studies are phase‑3 trials; the results are promising but not yet part of an approved indication.
What are the most common side effects and how are they managed?
Gastro‑intestinal symptoms such as nausea, vomiting, diarrhoea and constipation are most common, usually mild to moderate. They often improve with gradual dose escalation; anti‑emetics or dietary adjustments may be used, and treatment may be paused if severe.
How does tirzepatide compare with semaglutide for weight loss?
In a direct head‑to‑head trial, tirzepatide reduced body weight by about 20.2% versus 13.7% with semaglutide after 72 weeks, and also produced greater reductions in waist circumference. Both agents share similar gastrointestinal tolerability profiles.
Who should not use tirzepatide?
Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are generally excluded from GLP‑1‑based therapies. Caution is also advised for those on insulin or sulfonylureas due to hypoglycaemia risk, and for individuals with severe gastrointestinal disease.
What is Tirzepatide?
Tirzepatide is a synthetic peptide that activates both the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors. It is administered as a once‑weekly subcutaneous injection and is approved for the treatment of type 2 diabetes and obesity. Clinical trials have shown substantial weight loss, improved glycaemic control, and potential benefits in heart failure with preserved ejection fraction and obstructive sleep apnea, positioning it as a versatile therapy for metabolic and cardiometabolic disorders.
What is Tirzepatide used for?
Tirzepatide is educationally associated with: Chronic Weight Management, Cardiovascular risk reduction, Non-alcoholic fatty liver disease (MASH/NASH), Reduction of obstructive sleep apnea severity, Appetite suppression and satiety, Weight loss / obesity management, Glycemic control in type 2 diabetes, Type 2 diabetes mellitus. Educational only — not medical advice.
How is Tirzepatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Tirzepatide?
Reported adverse effects include: Pancreatitis, Hypoglycemia, Injection site reactions, Constipation, Nausea, Vomiting, Injection site reaction, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Tirzepatide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma (MTC), Multiple endocrine neoplasia syndrome type 2 (MEN2), Medullary thyroid carcinoma (MTC), Pregnancy, Type 1 diabetes mellitus, Multiple endocrine neoplasia type 2 (MEN 2), Hypersensitivity to tirzepatide or excipients. Consult a qualified clinician before use.